生物活性肽-单核细胞迁移抑制因子研究进展

程浩; 芮耀诚; 章越凡; 李铁军

doi:10.3969/j.issn.1006-0111.2015.01.005

生物活性肽-单核细胞迁移抑制因子研究进展

doi: 10.3969/j.issn.1006-0111.2015.01.005

1.
安徽中医药大学药学院, 安徽合肥 230012
2.
第二军医大学药学院药理学教研室, 上海 200433
3.
安徽中医药大学药学院, 安徽合肥 230012;第二军医大学药学院药理学教研室, 上海 200433

基金项目: 国家科技重大专项项目:防治心肌缺血的抗炎短肽候选化合物研究(2013ZX09103001-005)

Research progress of bioactive peptide monocyte locomotion inhibitory factor

1.
School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China
2.
Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai 200433, China
3.
School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China;Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

摘要: 单核细胞迁移抑制因子(monocyte locomotion inhibitory factor,MLIF)是阿米巴原虫产生的具有抗炎作用的五肽。体内、外研究发现,MLIF可以发挥抗炎和免疫保护作用,对类风湿关节炎、神经损伤、心肌缺血、脑缺血及痴呆具有良好的保护作用。研究证明MLIF通过NF-κB 和MAPK信号通路调节炎症反应和免疫保护。笔者对MLIF的来源和生物活性做一综述。
- 单核细胞迁移抑制因子 /
- 炎症 /
- 免疫 /
- 生物活性肽
Abstract: Monocyte locomotion inhibitory factor(MLIF)was an anti-inflammatory pentapeptide produced by Entamoeba histolytica.In vivo and in vitro study showed that MLIF displayed anti-inflammatory and immune protection effects and MLIF had protective effects on rheumatoid arthritis,nerve injury,myocardial ischemia,cerebral ischemia and Alzheimer's disease.Studies had shown that MLIF regulated inflammatory response and immune protection through NF-κB and MAPK signal pathways.The sources and biological activities of MLIF were reviewed in this paper.
- monocyte locomotion inhibitory factor /
- inflammation /
- immune /
- bioactive peptide

[1]	王竹青, 李八方.生物活性肽及其研究进展[J].中国海洋药物杂志,2010,29(2):60-68.
[2]	Kretschmer RR,Collado ML,Pacheco MG,et al.Inhibition of human monocyte locomotion by products of Entamoeba histolytica[J].Parasite Immunol,1985,7:527-543.
[3]	López-Osuna M,Cárdenas G,Isario J,et al.Induction of protective immunity against experimental amebic abscess of the liver (EAAL) using the monocyte locomotion inhibitory factor (MLIF) produced by Entamoeba histolytica:a preliminary report[J].Arch Med Res,2000, 31(4):S110-S111.
[4]	Jiang HF,Li J,Zhao X,et al.Determination of an unstable pentapeptide,monocyte locomotion inhibitory factor,in dog blood by LC-MS/MS:application to a pharmacokinetic study[J].J Pharm Biomed Anal,2013,83:305-313.
[5]	Giménez-Schr JA,Arenas E,Díaz L,et al.Effect of the monocyte locomotion inhibitory factor (MLIF) produced by Entamoeba histolytica on the expression of cell adhesion molecules in the skin of guinea pigs[J].Arch Med Res,2000,31(4 Suppl):S92-S93.
[6]	Godina-Gonzalez S,Furuzawa-Carballeda J,Utrera-Barillas D,et al.Amebic monocyte locomotion inhibitory factor peptide ameliorates inflammation in CIA mouse model by downregulation of cell adhesion,inflammation/chemotaxis,and matrix metalloproteinases genes[J].Inflamm Res,2010,59(12):1041-1051.
[7]	Velázquez JR,Garibay-Martínez L,Martínez-Tejada P,et al.An amebic anti-inflammatory peptide down-regulates ex vivo IL-1β expression in patients with rheumatoid arthritis[J].Reumatol Clin,2012,8(6):315-320.
[8]	章越凡,芮耀诚,李铁军,等.五肽代谢物在制备抗炎药物中的应用[P].中国专利,CN 103611149 A,2014-03-05.
[9]	Utrera-Barillas D,Velazquez JR,Enciso A,et al.An anti-inflammatory oligopeptide produced by Entamoeba histolytica down-regulates the expression of pro-inflammatory chemokines[J].Parasite Immunol,2003,25(10),475-482.
[10]	Silva-García R,Estrada-García I,Ramos-Payán R,et al.The effect of an anti-inflammatory pentapeptide produced by Entamoeba histolytica on gene expression in the U-937 monocytic cell line[J].Inflamm Res,2008,57(4):145-150.
[11]	Morales-Martínez ME,Silva-García R,Soriano-Correa C,et al.The Cys-Asn-Ser carboxyl-terminal end group is the pharmacophore of the amebic anti-inflammatory monocyte locomotion inhibitory factor (MLIF)[J].Mol Biochem Parasitol,2008,158(1):46-51.
[12]	Barrientos-Salcodo C,Rico-Rosillo G,Giménez-Scherer JA,et al.Computational study of the electronic structure characterization of a novel anti-inflammatory tripeptide derived from monocyte locomotion inhibitory factor (MLIF)-pentapeptide[J].Eur J Med Chem,2009,44 (8):3114-3119.
[13]	Rojas-Dotor S,Perez-Ramos J,Gimenez-Scherer,et al.Effect of the monocyte locomotion inhibitory factor (MLIF) produced by E.histolityca on cytokines and chemokine receptors in T CD4⁺ lymphocytes[J].Bio Res,2009,42 (4):415-425.
[14]	Rojas-Dotor S,Rico G,Pérez J,et al.Cytokine expression in CD4⁺ cells exposed to the monocyte locomotion inhibitory factor produced by Entamoeba histolytica[J].Parasitol Res,2006,98(5):493-495.
[15]	Rico G,Leandro E,Rojas S,et al.The monocyte locomotion inhibitory factor produced by Entamoeba histolytica inhibits induced nitric oxide production in human leukocytes[J].Parasitol Res,2003,90 (4),264-267.
[16]	Zhang Y,Chen J,Li F,et al.A pentapeptide monocyte locomotion inhibitory factor protects brain ischemia injury by targeting the eEF1A1/endothelial nitric oxide synthase pathway[J].Stroke,2012,43(10):2764-2773.
[17]	杨鹏远,芮耀诚,章越凡.多肽小分子在制备防治缺血性脑血管病药物中的应用[P].中国专利,CN 101361961 A,2009-2-11.
[18]	章越凡,芮耀诚,李铁军,等.五肽代谢物及其在制备防治缺血性脑血管疾病药物中的应用[P].中国专利,CN 103611149 A,2014-03-05.
[19]	芮耀诚,李铁军,杨鹏远,等.多肽小分子MLIF在制备防治心肌缺血药物中的应用[P].中国专利,CN 101612384A,2009-12-30.
[20]	李铁军,芮耀诚,章越凡,等.一种五肽的部分代谢物用于制备抗心肌缺血产品的新用途[P].中国专利,CN 103203009 A,2013-07-17.
[21]	Yao J,Xu Y,Ji F,et al.Protective effects of MLIF analogs on cerebral ischemia-reperfusion injury in rats[J].Peptides,2011,32(5):1047-1054.
[22]	Bermeo G,Ibarra A,García E,et al.Monocyte locomotion inhibitory factor produced by E.histolytica improves motor recovery and develops neuroprotection after traumatic injury to the spinal cord[J].Biomed Res Int,2013,2013:340727.
[23]	李铁军,芮耀诚,章越凡,等.一种五肽及其代谢物用于制备抗痴呆产品的新用途[P].中国专利,CN 103191407,2013-07-10.
[24]	Silva-Garcia R,Rico-Rosillo G.Anti-inflammatory defense mechanisms of Entamoeba histolytica[J].Inflamm Res,2011,60(2):111-117.
[25]	Sasaki M,Kashima M,Watanabe A,et al.Differential regulation of metalloproteinase production,proliferation and chemotaxis of human lung fibroblasts by PDGF,interleukin-1beta and TNF-alpha[J].Mediators Inflamm,2000,9(3-4):155-160.
[26]	Gharaee-Kermani M,Phan SH.Role of cytokines and cytokine therapy in wound healing and fibrotic diseases[J].Curr Pharm Des,2001,7(11):1083-1103.
[27]	Velazquez JR.The monocyte locomotion inhibitory factor an anti-inflammatory peptide;therapeutics originating from amebic abscess of the liver[J].Recent Pat Endocr Metab Immune Drug Discov,2011,5(1):7-12.
[28]	Silva-García R,Rico-Rosillo G.Anti-inflammatory defense mechanisms of Entamoeba histolytica[J].Inflamm Res,2011,60(2):111-117.

[1]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
[2]	迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛. 负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
[3]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[4]	冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军. 雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055
[5]	修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星. 全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 291-296. doi: 10.12206/j.issn.2097-2024.202312054
[6]	姜涛, 徐卫凡, 蒋益萍, 夏天爽, 辛海量. 巴戟天丸组方对Aβ损伤成骨细胞的作用及基于网络药理学的机制研究 . 药学实践与服务, 2024, 42(7): 285-290, 296. doi: 10.12206/j.issn.2097-2024.202305011
[7]	毛智毅, 王筱燕, 陈晓颖, 汤逸斐. 度拉糖肽联合二甲双胍对肥胖型2型糖尿病患者机体代谢、体脂成分及血清脂肪因子的影响 . 药学实践与服务, 2024, 42(7): 305-309. doi: 10.12206/j.issn.2097-2024.202305032
[8]	刘汝雄, 杨万镇, 涂杰, 盛春泉. 铁死亡调控蛋白GPX4的小分子抑制剂研究进展 . 药学实践与服务, 2024, 42(9): 375-378. doi: 10.12206/j.issn.2097-2024.202312075
[9]	陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾. 基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 1-8. doi: 10.12206/j.issn.2097-2024.202401073
[10]	张莲卿, 骆岩, 杨提, 姚佳晨, 李文艳. 基于FAERS数据库的艾塞那肽微球不良事件信号挖掘与研究 . 药学实践与服务, 2024, 42(10): 445-450. doi: 10.12206/j.issn.2097-2024.202403057
[11]	景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞. 黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
[12]	赖立勇, 夏天爽, 徐圣焱, 蒋益萍, 岳小强, 辛海量. 中药青蒿抗氧化活性的谱效关系研究 . 药学实践与服务, 2024, 42(5): 203-210, 216. doi: 10.12206/j.issn.2097-2024.202211012
[13]	杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛. 正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
[14]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[15]	顾佳钰, 胡馨儿, 王晓飞, 张颖, 张海, 曹岩. 侧流免疫层析定量检测方法的研究进展 . 药学实践与服务, 2024, 42(7): 273-277, 284. doi: 10.12206/j.issn.2097-2024.202307037
[16]	马兹芬, 许维恒, 金煜翔, 薛磊. 食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
[17]	岳春华, 贲永光, 王海桥. 基于NLRP1炎症小体探讨百合知母汤抗抑郁的作用机制 . 药学实践与服务, 2024, 42(8): 325-333. doi: 10.12206/j.issn.2097-2024.202401033
[18]	张广雨, 杜晶, 刘梦珍, 朱丹妮, 闫慧, 刘冲. 新斯的明与山莨菪碱联合应用对肺型氧中毒的保护作用及其机制的研究 . 药学实践与服务, 2024, 42(10): 433-438, 444. doi: 10.12206/j.issn.2097-2024.202310049
[19]	宋泽成, 陈林林, 鲁仁义, 刘梦肖, 王彦. 脓毒症治疗的研究进展 . 药学实践与服务, 2024, 42(11): 1-5. doi: 10.12206/j.issn.2097-2024.202405059

点击查看大图

计量

文章访问数: 3095
HTML全文浏览量: 269
PDF下载量: 134
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

生物活性肽-单核细胞迁移抑制因子研究进展

doi: 10.3969/j.issn.1006-0111.2015.01.005

Research progress of bioactive peptide monocyte locomotion inhibitory factor

计量

生物活性肽-单核细胞迁移抑制因子研究进展

doi: 10.3969/j.issn.1006-0111.2015.01.005

1. 安徽中医药大学药学院, 安徽合肥 230012

2. 第二军医大学药学院药理学教研室, 上海 200433

3. 安徽中医药大学药学院, 安徽合肥 230012;第二军医大学药学院药理学教研室, 上海 200433

English Abstract

Research progress of bioactive peptide monocyte locomotion inhibitory factor

全文HTML

目录

留言板

生物活性肽-单核细胞迁移抑制因子研究进展

doi: 10.3969/j.issn.1006-0111.2015.01.005

Research progress of bioactive peptide monocyte locomotion inhibitory factor

计量

出版历程

生物活性肽-单核细胞迁移抑制因子研究进展

doi: 10.3969/j.issn.1006-0111.2015.01.005

1. 安徽中医药大学药学院, 安徽 合肥 230012 2. 第二军医大学药学院药理学教研室, 上海 200433 3. 安徽中医药大学药学院, 安徽 合肥 230012;第二军医大学药学院药理学教研室, 上海 200433

English Abstract

Research progress of bioactive peptide monocyte locomotion inhibitory factor

全文HTML

目录

1. 安徽中医药大学药学院, 安徽合肥 230012

2. 第二军医大学药学院药理学教研室, 上海 200433

3. 安徽中医药大学药学院, 安徽合肥 230012;第二军医大学药学院药理学教研室, 上海 200433